Kymera Therapeutics (KYMR) Misses Q3 EPS by 18c

Kymera Therapeutics (NASDAQ: KYMR) reported Q3 EPS of ($0.94), $0.18 worse than the analyst estimate of ($0.76).

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Lion Copper and Gold Corp. to rename and consolidate shares for Nasdaq bid
• Golden Minerals names new CEO as partner eyes Argentine asset sale